Compare AMTD & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTD | ACHV |
|---|---|---|
| Founded | 2003 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.2M | 726.5M |
| IPO Year | 2019 | 2018 |
| Metric | AMTD | ACHV |
|---|---|---|
| Price | $0.73 | $7.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 5.3K | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $2.62 |
| 52 Week High | $1.65 | $8.64 |
| Indicator | AMTD | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 48.49 |
| Support Level | N/A | $7.01 |
| Resistance Level | $0.80 | $8.63 |
| Average True Range (ATR) | 0.04 | 0.37 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 5.10 | 40.43 |
AMTD IDEA Group is a diversified institution and digital solutions conglomerate group, connecting companies and investors with world-wide markets. The group operates its businesses in five reportable and operating segments: capital market solutions segment, digital solutions and other services segment, media and entertainment segment, hotel operations, hospitality and VIP services segment, and strategic investment segment. The group generates the majority of its revenue from the strategic investment segment that engages in proprietary investments and management of world-wide investment portfolio (including listed and unlisted equity shares investments and movie rights investments). Its geographic areas are China, Europe, America, and Southeast Asia.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.